BiOMViS is a biotech company focused on developing innovative prophylactic and immunotherapeutic solutions for infectious diseases and cancer. Central to their approach is a proprietary vaccine platform that utilizes genetically reprogrammed, non-pathogenic E. coli strains as efficient factories for producing outer membrane vesicles (OMVs). These OMVs are engineered to be low in reactogenicity and enriched with vaccine antigens, allowing for a more effective immune response. The platform's unique features include precision engineering expression vectors that facilitate the accumulation of high quantities of vaccine antigens in the OMV compartment, as well as a streamlined production process that enhances yield and reduces costs.

The BiOMViS technology overcomes traditional limitations associated with wild-type E. coli strains, which typically produce low amounts of OMVs and carry unwanted proteins that can dilute immune responses. By employing strains like E. coli BL21Δ60, which can release up to 50 mg/L of OMVs—significantly higher than conventional strains—BiOMViS ensures a potent delivery of vaccine antigens. The simplicity of their production process, which involves fermentation, separation, and ultrafiltration, further positions BiOMViS as a leader in the field of vaccine development, making their approach both efficient and cost-effective.

Italy

BiOMViS Srl is a Biotech Company committed to foster prophylactic and immunotherapeutic interventions in infectious diseases and cancer.

BiOMViS

Company Details